Trial Profile

A phase 1 open label trail in patients with ROR1‑positive solid tumors and patients with ROR1‑positive platinum‑resistant ovarian cancer or endometrial cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2025 Status changed from planning to withdrawn prior to enrolment. According to a Lyell Immunopharma media release, Lyell has streamlined its operations and is discontinuing development of LYL119,to focus resources on acceleration of pivotal trials of IMPT-314 and next-generation solid tumor CAR T cell programs in preclinical development.
07 Nov 2024 According to a Lyell Immunopharma media release, site selection and initiation is progressing well for Phase 1 trial of LYL119.
13 Aug 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com